Eli Lilly has agreed to acquire the financially troubled Adverum Biotechnologies, marking a strategic move to penetrate the lucrative market for wet age-related macular degeneration (AMD). This acquisition comes at a time when the demand for innovative therapies in ophthalmology is surging, particularly for conditions that lead to vision loss in an aging population.
The wet AMD market is characterized by its high treatment costs and the potential for significant revenue generation, making it an attractive target for pharmaceutical companies. By integrating Adverum’s gene therapy platform, which focuses on delivering long-lasting treatments for retinal diseases, Lilly aims to enhance its portfolio and establish a stronger foothold in this competitive sector.
This acquisition not only reflects Lilly’s commitment to expanding its ophthalmology offerings but also highlights the ongoing trend of larger pharmaceutical companies seeking to bolster their pipelines through strategic acquisitions of smaller biotech firms, particularly those with promising technologies in high-demand therapeutic areas.
Use the database as your supply chain compass →
